The therapeutic effect of radioimmunotherapy depends on the distribution of the absorbed dose in relation to viable cancer cells within the tumor, which in turn is a function of the activity distribution. The aim of this study was to investigate the distribution of 177 Lu-DOTA-BR96 monoclonal antibodies (mAbs) targeting the Lewis Y antigen over 7 days using a syngeneic rat model of colon carcinoma.
INTRODUCTION
The limited success of radioimmunotherapy against solid tumors can be partly attributed to the difficulty in achieving high tumor uptake and penetration of radiolabeled monoclonal antibodies (mAbs) (1, 2) . Aspects of the microenvironment of solid tumors that limit the distribution of antibodies throughout viable regions include abnormal vasculature, high interstitial fluid pressure and impaired lymphatic drainage (3) (4) (5) , as well as the composition of the extracellular matrix (6, 7) . The antibody characteristics are also important for the microdistribution; for example, high-affinity antibodies risk entrapment in perivascular regions at a "binding site barrier" (8, 9) , and those targeting an intracellular antigen preferentially collect in necrotic areas (10, 11) . Additionally, during the time of antibody uptake, the tumor is a dynamic system with regard to treatment effects, repopulation, and angiogenesis, all of which can affect antibody distribution (12) .
Colorectal carcinoma is the third most common cancer in humans (13) and is prone to metastasize (14) , which makes it suitable for systemic treatment strategies like radioimmunotherapy. Several preclinical studies have been performed on the intratumoral distribution of antibodies, primarily targeting carcinoembryonic antigen (CEA) in immunedeficient mice bearing subcutaneous xenografts of human colorectal cancers (15) (16) (17) (18) (19) (20) .
However, such xenografts are artificial tumor models with little interaction with the host, e.g. with a low probability of metastasizing, and with stromal and vascular interactions not similar to human cancers (21) . To better mimic the clinical situation, our group has established a syngeneic rat model of colon carcinoma for radioimmunotherapy using the mAb BR96 that targets the tumor-associated antigen Lewis Y (Le y ) (22) . For labeling we used Lutetium-177 (T ½ =6.73 days) which is both a beta (79% E βmax =498 keV, 12% E βmax =177 keV, 9% E βmax =385 keV) and gamma (10% E γ =208 keV, 6% E γ =113 keV) emitter.
In this study we investigated the distribution of the radiolabeled antibody within tumors at different time points up to 7 days post-injection (p.i.) in relation to histology, antigen expression and vascularization. We also calculated the intratumoral absorbed-dose rate distribution at the time of sacrifice in relation to the same factors.
MATERIALS AND METHODS

Monoclonal Antibody
The chimeric (mouse/human) monoclonal IgG1 antibody BR96 (Seattle Genetics Inc., Seattle, WA) binds to the tumor-associated antigen Le y . Several human carcinoma types express Le y , including breast, gastrointestinal tract, pancreas, non-small-cell lung, cervical and ovarian cancers. BR96 also binds to some normal tissues, mainly epithelial cells of the gastrointestinal tract (23) . The dissociation constant (K d ) is 4 nM (22) .
Radioimmunoconjugate
BR96 was conjugated with the DOTA chelate (S-2-(4-isothiocyanatobenzyl)-1,4,7,10tetraazacyclododecane tetraacetic acid; Macrocyclics, Dallas, TX) as previously described (22) . The number of DOTA moieties per BR96 molecule was determined by matrix-assisted laser desorption ionization mass spectroscopy (MALDI-MS). The antigen-binding properties (immunoreactivity) of DOTA-BR96 relative to BR96 were determined by saturation binding curve analysis, using BN7005 cells as the target antigen. The immunoreactivity is given by the ratio: K d (BR96)/K d (DOTA-BR96).
The following procedure was used for labeling with 177 LuCl 3 (MDS Nordion, Vancouver, Canada). Both the DOTA-BR96 conjugate in 0.25 M ammonium acetate buffer and the radionuclide solution were preheated at 45°C for 10 min. The DOTA-BR96 solution was then 6 added to the radionuclide-containing vial and incubated at 45°C for 15 min. The reaction was quenched with an excess of DTPA for 5 min and diluted in 1% human serum albumin (HSA, Baxter Medical AB, Kista, Sweden). The radiochemical purity of the labeled immunoconjugate was determined by instant thin-layer chromatography (ITLC) using a 1 x 9 cm silica-gel-impregnated fiberglass sheet, eluted in 0.1 M EDTA. Separation by sizeexclusion chromatography together with high-performance liquid chromatography (HPLC) (7.8 x 300 mm molecular sieving column, Phenomenex SEC S3000; Phenomenex, Torrance, CA, eluted in 0.05 M sodium phosphate at 1.0 mL/min) was used to determine the radiochemical purity and to detect signs of aggregation or fragmentation.
Rat Tumor Model
Immunocompetent male Brown Norway (BN) rats (n=38 for the main study; Harlan, Horst, the Netherlands) with a mean body weight of 214 g (SD 24 g) at the time of tumor cell inoculation were used. These animals express BR96-binding antigen in some normal tissues, mainly in the epithelium of the gastrointestinal tract (24) . The animals were housed under standard conditions with standard pellets and fresh water ad libitum. All experiments were conducted in compliance with Swedish legislation on animal protection, and were approved by the regional ethics committee on animal experiments. 
Study Design and Biodistribution
The main study was conducted as two separate experiments referred to as Group 1 and Group 2 ( Table 1 ). Tumors were measured and volumes were calculated as length x width 2 x 0.4, as previously established (25) Arterial blood samples were drawn 2 min p.i. and before sacrifice for activity measurements in a NaI(Tl) well counter (Group 1: 1282 Compugamma CS; LKB Wallac, Turku, Finland; Group 2: Wallac Wizard 1480, PerkinElmer, Shelton, CT). Animals were euthanized 2, 8, 24, 48, 72, 96, 120 and 168 h p.i., and the tumors were excised and cut in half. One half was embedded in Tissue-Tek® O.C.T.™ compound (Sakura Finetek, Zoeterwoude, the Netherlands) and frozen on dry ice, and the activity of the other half was measured in a NaI(Tl) well counter. The frozen samples were cryosectioned, starting at the tumor center.
Sections used for autoradiography were 20 µm (Group 1) or 30 µm (Group 2) thick. Sections used for staining were 10 µm thick and stored at -80°C.
Control of Antibody Effects
In order to evaluate untreated tumor histology and antigen expression and the therapeutic effects of the unlabeled antibody, 18 rats were inoculated with tumor cells as described above.
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Tumors from 9 untreated rats were excised on the day corresponding to antibody injection.
The remaining 9 rats were injected with 0.1, 1.0 or 10.0 mg/kg unlabeled BR96 (n=3/group) and sacrificed 48 h p.i. The tumors were fixed in 4% paraformaldehyde and paraffin embedded before sectioning and staining for histology and antigen expression.
Digital Autoradiography
The 177 Lu activity distribution was imaged using microscope slides containing 3 tumor sections per slide. These were imaged for 10 hours each, using a double-sided silicon strip detector with an intrinsic spatial resolution of 50 µm (Biomolex 700 Imager, Biomolex AS, Norway). The recorded coordinates of all detected event were analyzed using IDL 6.4 software (ITT Visual Information Solutions, Boulder, CO). Corrections were applied for dead or miscalibrated strips, and for radioactive decay.
To determine the detector efficiency for each section thickness, adjacent tumor sections were imaged and their activity measured in the NaI(Tl) well counter for quantification of all tumor section images. The total mass of the sections on each slide was calculated by the section thickness times the density (1.0 g/cm 3 ) times the area determined from histology stainings.
Images were scaled to percent injected activity per gram (%IA/g) using the mass, the total activity per section and the decay-corrected injected activity. Visualization and region-ofinterest (ROI) based analysis of the images were performed using ImageJ software (26) . Six ROIs (0.1-4.5 mm 2 in size) were drawn on one tumor section per animal; two regions each outlining structures visually identified as having high, medium and low levels of activity uptake relative to the entire section.
Dosimetry
In order to calculate the absorbed-dose rate distribution in tumor sections at the time of sacrifice, a point-dose kernel (PDK) (27) for 177 Lu was generated with the Monte Carlo code 9 MCNP5 1.4 (28) utilizing the new electron transport logic (dbcn 17j 2). The PDK was modeled as concentric spheres with radii increasing in steps of 100 µm inside a 2.1 mm diameter cube in a tissue-equivalent medium (1.00 g/cm 3 ). Simulations included beta particles, gamma rays, conversion electrons, and Auger electrons emitted at the origin, with the energy deposition tallied in each layer. One imaged section per tumor was used. Each image was normalized to the activity at the time of sacrifice and stacked to form a new threedimensional dataset with the shortest diameter matching that of the PDK. The volume was down-sampled to cubic voxels with 100 µm sides before convolution with the PDK. The resulting absorbed-dose rate image was then extracted from the middle of the stack. Mean absorbed-dose rate for the whole section and in ROIs corresponding to those in the activity image were quantified.
Histology and Immunohistochemistry
After autoradiography, the sections used for detection and adjacent sections were stained with Mayer's Hematoxylin and Chromotrope 2R (both from Histolab AB, Gothenburg, Sweden).
Sections were stained for the detection of antigen expression (BR96), blood vessel distribution (RECA-1, Abcam plc, Cambridge, UK) and proliferation (anti-Ki67 clone SP6, Thermo Fisher Scientific Inc., Fremont, CA). The slides were dried for 15 min at 37°C and then fixed either for 8 min with 4% phosphate-buffered formalin (Histolab AB, for antigen and proliferation staining) or for 5 min in ice-cold acetone (for staining of blood vessels). The sections were then washed with TRIS-buffered saline with Tween 20, pH 7.4 and blocked of endogenous peroxidases by Peroxidase blocking solution (Dako, Glostrup, Denmark), before the addition of primary antibodies. All antibodies were diluted in Antibody Diluent (Dako).
Slides were incubated with the primary antibodies either overnight (BR96 and RECA-1) or for 2 h (SP6) in a moist chamber at room temperature. After washing, secondary antibodies were added to the slides. The secondary antibodies used were peroxidase-conjugated donkey anti-human IgG for the detection of BR96, peroxidase-conjugated donkey anti-mouse IgG for the detection of RECA-1, and peroxidase-conjugated donkey anti-rabbit IgG for the detection of SP6 (all from Jackson ImmunoResearch Laboratories Inc. West Grove, PA). Slides were incubated for either 3 h (BR96 and RECA-1) or 1 h (SP6) in a moist chamber at room temperature. After washing, diaminobenzidine (Dako) was added before hematoxylin staining (1 min) and subsequent dehydration and mounting.
Areas corresponding to the ROIs were exported as individual images from adjacent sections stained for the detection of antigen expression, and processed to suppress blue cell nuclei staining. The ratio of stained to non-stained areas in each image was then calculated using Aperio ImageScope software (Aperio Technologies, Vista, CA) and the Positive Pixel Count v9 algorithm. Algorithm parameters were calibrated separately per group of animals due to different staining intensities. (Supplemental Fig. 1 ).
Statistical Analysis
To test the image quantification, the values of the mean %IA/g obtained from the digital autoradiography images were compared to the corresponding values from NaI(Tl) well counter measurements for the same tumors using a paired-samples t-test. The activities measured by well counter for animal Groups 1 and 2 were also compared at each time point p.i., using the nonparametric independent-samples Mann-Whitney U test. The Pearson correlation between the antigen staining ratio and the activity uptake, as well as the estimated absorbed-dose rate in the ROIs was calculated at each time point that had data from at least 5 animals, i.e. 30 ROIs. Normal distribution was assumed in this test due to the number of samples. All analyses were performed with IBM SPSS Statistics version 19 (SPSS Inc., Chicago, IL); p < 0.05 being considered significant.
RESULTS
Radioimmunoconjugation
The mean number of DOTA molecules per IgG was determined to be 2.4. The immunoreactivity was given by the ratio of the dissociation constant for BR96 and DOTA-BR96, and was found to be 0.86, which was not significantly different from unlabeled BR96.
The specific activity used for Group 1 was 86 MBq/mg, the radiochemical purity according to ITLC was >99%, and no aggregates or fragments were observed with HPLC. The specific activity used for Group 2 was 42.5 MBq/mg, the radiochemical purity was >97.5%, and 1.3% labeled aggregated fraction according to HPLC.
Biodistribution
Biodistribution data for blood and tumors are presented in Table 2 . Pharmacokinetic analysis of the decay-corrected %IA/g for blood resulted in a t½α of 5.6 h and t½β of 32.5 h (nonlinear regression, two-phase decay, GraphPad Prism 5.04). The mean tumor volume at injection was 650 mm 3 (SD 235 mm 3 ) and the median tumor uptake was 8.4 %IA/g (range 6.3-9.8 %IA/g) at 48 h p.i., after which there were increased variations in uptake and tumor volumes. Of the 18 tumors excised 72 h or later, three had continued to grow, four had minor changes in volume, and 11 had decreased in size. No statistically significant difference in tumor %IA/g could be found between the two groups of animals at any time point p.i. using a nonparametric test. No significant difference that would indicate a systematic error in image quantification was found between tumor activity uptake measured by well counter or by quantitative autoradiography.
Absorbed-Dose Rate at Moment of Sacrifice
Images of the absorbed-dose rate distributions were produced from digital autoradiography images. The intratumoral absorbed-dose rate distribution closely mimics the activity distribution ( Fig. 1) as most of the energy is deposited close to the point of decay. Table 3 shows the median values and ranges for the mean absorbed-dose rate over the entire section are presented for each time point and animal group.
Activity Distribution in Comparison to Tumor Histology, Antigen Expression and
Vascularization At 2 and 8 h p.i., the radioactivity was mainly distributed close to viable and antigen-positive tumor margins (Fig. 1A) . The stainings showed dense tumor growth with necrotic areas at the center of the tumors. All tumors were well vascularized, contained a high proportion of proliferating cells, and the Le y antigen was detectable on almost all viable tumor cells. At 24 h p.i., the activity had penetrated into the more central areas of the tumor sections, however, higher levels were still observed peripherally in half of the evaluated tumors. The areas with high activity correlated mainly to antigen-positive areas in the viable regions ( Fig. 1B) .
Tumors were well vascularized and some also had small areas of granulation tissue. At 48 h p.i., there was a change in histology compared to untreated controls ( Fig. 2A, B) , with areas of granulation tissue that overlapped activity hot spots in 5 of 6 tumors (Fig. 1C ). Areas with low activity had high levels of available antigen and blood vessels were detected in all areas.
At 72-168 h p.i., the activity distribution varied between the individual tumors; ranging from local areas of high activity to a more homogeneous distribution. Tumors that decreased in size after the mAb injection contained few blood vessels and few proliferative cells, whereas the opposite was observed for the tumors that continued to grow. Small tumors had fewer antigen-positive cells and a larger proportion of stroma or granulation tissue, often with high activity uptake, while larger tumors had dense areas of tumor cells and intense staining of the 13 antigen, typically with limited uptake (Fig. 1D ). There was no notable uptake in the necrotic areas over the time observed.
Control of Antibody Effects
Tumor cells from untreated animals all had complete membrane staining for the Le y antigen (Fig. 2B) . The low BR96 dose of 0.1 mg/kg resulted in small areas of unstained tumor cells close to the tumor margins. Both 1.0 and 10.0 mg/kg led to limited antigen staining and altered histology, including the formation of granulation tissue and necrosis, while untreated and low dose animals all showed dense growth of tumor cells with occasional areas of necrosis ( Fig. 2) .
Region of Interest Analysis
The mean activity per gram, the mean absorbed-dose rate at the time of sacrifice, and the percentage of the area stained as antigen-positive were calculated for each ROI. The absorbed-dose rate in the high uptake regions ( Table 3 ) was found to be approximately twice as high as the mean absorbed-dose rate for the whole section. The results of the Pearson correlation analysis of the relationships between activity uptake and absorbed-dose rate, and the antigen-positive area are given in Table 4 . The correlation coefficient changed over time, from positive at 8 and 24 hours p.i. to negative from 48 h p.i. and onwards (Fig. 3) . Activity uptake and absorbed-dose rate exhibited very similar correlations with antigen though the correlation with absorbed-dose rate was stronger at earlier than at later time points.
DISCUSSION
The results of this study show the dynamic process of intratumoral antibody distribution in a syngeneic animal model, and also how heterogeneous distribution results in a considerable variation in the absorbed-dose rate. Initially, the activity was localized to the periphery of the tumor, presumably near perfused blood vessels, followed by a comparatively homogeneous distribution corresponding to viable antigen-expressing tumor tissue at 24 h p.i. The subsequent trend of increasing correlation between activity uptake and granulation tissue was interpreted as the effect of treatment, reducing viable, antigen-positive tumor cells in areas with high activity uptake. Activity uptake does not necessarily infer antibody uptake, since it is not known whether the radionuclide was still coupled to the mAb or free after degradation, or if the mAb was intact or fragmented. The ROI-based analysis showed a negative correlation between antigen expression and activity uptake from 48 h p.i. and onwards. This correlation was stronger than that reported previously by Flynn et al. (16) who based their results on a pixel-by-pixel correlation between CEA and antibody in a subcutaneous xenograft. While the methods of analysis differ, it is also likely to be an effect of the differences in antigen expression, vascularization and immune response between the animals used (17) . The increased variance in tumor uptake after 48 h p.i. was attributed to variations in tumor growth or reduction, as has been observed elsewhere (19) . The new cell populations present in several tumors had little activity uptake, probably due to lower antibody concentration in the blood. This increased variance is likely more evident in syngeneic animal tumor models, which often show a faster rate of proliferation compared to human tumors (21) .
No correlation was apparent between individual tumor growth or reduction and intratumoral activity distribution in this study.
Starting at 24 h p.i., the histological properties of the tumors changed from predominantly proliferative tumor cells to areas of granulation tissue, concurrent with a decrease in tumor volumes. In order to study the mAb distribution separately from radio-therapeutic effects, the administered activities were lower than those needed for clinical response according to our previous work (22) . Therefore, these effects may be due to an immunological response mediated via the Fc region of the antibodies (29, 30) . This is supported by the presence of granulation tissue in tumors from animals treated with unlabeled BR96 but not in untreated controls. At therapeutic activities of 177 Lu (400 MBq/kg), the decrease in peripheral leukocytes (22) probably results in an impaired immune response. Instead, with absorbeddose rates and total absorbed doses approximately 8 times higher than in this study, radiationinduced cell death might dominate in achieving complete response (31) .
Calculations of absorbed-dose rate distributions at different time points showed that highuptake regions are exposed to twice the absorbed-dose rate compared to the whole tumor section mean. Estimating the accumulated mean tumor absorbed doses over several days from the calculated absorbed-dose rates showed that they would fall in the area of several grays at late time points, absorbed doses leading to the majority of cells dying if given at a single instant in an in vitro assay. However, the low 177 Lu activity and absorbed-dose rate in this study may allow the tumor to repair DNA damage and repopulate by proliferation of undamaged or restored cells. The correlation between viable, antigen-expressing tissue and areas of relatively high absorbed-dose rate at 24 h p.i. indicates that using a longer-range beta emitter such as 90 Y would not necessarily increase tumor cell death at therapeutic activities. In contrast, the concentration of activity in areas of granulation tissue and stroma at later times suggests that a radionuclide with a shorter half-life than that used in the present study would be more beneficial. Further studies, particularly at therapeutic activity levels, are needed to fully evaluate the effects of the intratumoral temporal activity distribution on the efficacy of radioimmunotherapy in relation to radionuclide half-life and emission properties.
Earlier studies using models of colorectal cancer in immune-deficient mice show limited agreement with our observations of activity accumulation in granulation and stromal tissue at later time points. Two studies report the uptake of 125 I-labeled anti-CEA antibody in necrotic areas at 48 h p.i. and onwards, although this is most likely an effect of free antibody or iodine pooling in blood (16, 19) . Studies of anti-CEA antibodies in subcutaneous xenografts of well differentiated and regularly vascularized tumors exhibited a similar pattern of uptake to that in our model, while the antibody never penetrated very far from the blood vessels in poorly differentiated and vascularized tumors (17) . Observations of another antibody, A33, in a welldifferentiated model also showed early uptake around blood vessels resulting in homogeneous tumor uptake by 48 h p.i. (15) . Anti-CEA antibodies had penetrated well-vascularized intrahepatic xenografts effectively at 24 h p.i. (18) (19) (20) , which is more in agreement with our results, compared with subcutaneous tumors of the same cell line (17, 32) . Lower-affinity antibodies (e.g. anti-HER2) penetrate tumors more efficiently (9) , and modeling predicts that binding-site barrier effects are unlikely for mAbs with K d >1 nM (33) , such as BR96 (K d =4 nM). The observed reduction in tumor cell density around 24-48 h p.i. could also affect the activity distribution since apoptosis-inducing pretreatment has been shown to increase the rate and extent of antibody penetration (12, 34) .
CONCLUSION
The results of this study show the initial process of antibody penetration into viable antigenexpressing tumor areas over approximately 24 hours, followed by a decreasing association between activity uptake and viable, antigen-expressing tumor tissue over a period of several days. This indicates that delivering a high absorbed-dose rate during the initial penetration and uptake period is especially important for a therapeutic response. 
